Life-threatening digoxin toxicity with ventricular fibrillation: when initial digoxin immune Fab is insufficient
This protocol addresses patients with cardiac glycoside toxicity who present with life-threatening signs — including ventricular arrhythmia, asystole, severe hyperkalaemia, or haemodynamic compromise — are not in cardiac arrest, and have not achieved full resolution after an initial course of digoxin immune Fab.
Clinical scenario
Life-threatening digoxin toxicity in a patient not in cardiac arrest, with one or more of the following:
- Ventricular tachycardia or fibrillation
- Asystole or symptomatic high-degree atrioventricular block
- Severe hyperkalaemia (serum potassium >6.5 mmol/L)
- Hypotension (systolic blood pressure <100 mmHg) with end-organ dysfunction
When initial treatment has not achieved targets
An initial dose of digoxin immune Fab was administered, with close monitoring targeting normalisation of serum potassium concentration, body temperature, blood pressure, ECG, and renal function. Where these endpoints remain unmet — particularly persistent hyperkalaemia, ongoing arrhythmia, or haemodynamic instability — escalation to this protocol is indicated.
Escalated treatment approach
The next step involves further administration of digoxin immune Fab in incremental doses, continued until toxicity resolves. The complete escalation criteria and management detail are in the full protocol.
Treatment goals: Resolution of digoxin toxicity, with normalisation of serum potassium concentration, ECG, and renal function.
References
DOI: 10.1097/MEJ.0000000000001065
- Ventricular tachycardia or fibrillation
- Asystole or symptomatic, high-degree atrioventricular block
- Severe hyperkalaemia (serum potassium >6.5 mmol/L)
- Hypotension (systolic blood pressure <100 mmHg) associated with end-organ dysfunction
- For all other cases of life-threatening digoxin toxicity (i.e. patients not in cardiac arrest), an initial dose of 1–2 vials should be sufficient for neutralisation of digoxin toxicity in most cases, and can be followed with incremental doses of 1–2 vials, until resolution of toxicity.
- Patients should be monitored closely after administration of digoxin immune Fab, including assessment of serum potassium concentrations, body temperature, blood pressure, ECG and renal function (serum urea and creatinine and estimated glomerular filtration rate); monitoring should continue until potassium concentration, ECG and renal function are ‘normalised’.
View source ↗